About: OncoMed

An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by and delisted from the Nasdaq.

Property	Value
dbo:abstract	OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by and delisted from the Nasdaq. (en)
dbo:assets	2.076E8
dbo:dissolutionDate	2019-04-23 (xsd:date)
dbo:fate	Acquired by Mereo BioPharma (en)
dbo:industry	dbr:Pharmaceutical
dbo:revenue	2.47E7
dbo:type	dbr:Public_company
dbo:wikiPageID	44570489 (xsd:integer)
dbo:wikiPageLength	11054 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1112516297 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Sanofi dbr:Bayer dbr:Pfizer dbr:Pharmaceutical dbr:University_of_Michigan dbr:Vantictumab dbr:Public_company dbr:Chief_executive_officer dbc:Pharmaceutical_companies_established_in_2004 dbr:GlaxoSmithKline dbr:Mountain_View,_California dbr:NASDAQ dbr:Board_of_directors dbr:California_Healthcare_Institute dbr:Stanford_University dbr:Stock_symbol dbr:Demcizumab dbr:Frizzled dbr:Dainippon_Sumitomo_Pharma dbr:Celgene dbr:DLL4 dbc:2004_establishments_in_California dbc:2019_mergers_and_acquisitions dbc:American_companies_established_in_2004 dbr:Brontictuzumab dbr:Palo_Alto,_California dbc:Companies_formerly_listed_on_the_Nasdaq dbr:Astellas_Pharma dbc:Companies_based_in_Redwood_City,_California dbr:Initial_public_offering dbr:NeXT dbr:Cancer_stem_cell dbr:Redwood_City,_California dbr:Seaport_Centre dbr:Biotechnology_Industry_Organization dbr:United_States_Adopted_Name dbr:Tarextumab dbr:IgG2 dbr:Ipafricept dbr:Mereo_BioPharma
dbp:assets	(en) 2.076E8
dbp:assetsYear	2016 (xsd:integer)
dbp:bloomberg	OMED:US (en)
dbp:defunct	2019-04-23 (xsd:date)
dbp:fate	Acquired by Mereo BioPharma (en)
dbp:foundation	dbr:University_of_Michigan
dbp:google	OMED (en)
dbp:industry	dbr:Pharmaceutical
dbp:locationCity	dbr:Redwood_City,_California
dbp:locationCountry	United States (en)
dbp:name	OncoMed (en) OncoMed Pharmaceuticals, Inc. (en)
dbp:revenue	(en) 2.47E7
dbp:secCik	1302573 (xsd:integer)
dbp:symbol	OMED (en)
dbp:tradedAs	NASDAQ:OMED (en)
dbp:type	dbr:Public_company Private (en)
dbp:wikiPageUsesTemplate	dbt:As_of dbt:Authority_control dbt:End_date dbt:Infobox_company dbt:Official_website dbt:Reflist dbt:Ubl dbt:Finance_links
dbp:yahoo	OMED (en)
dcterms:subject	dbc:Pharmaceutical_companies_established_in_2004 dbc:2004_establishments_in_California dbc:2019_mergers_and_acquisitions dbc:American_companies_established_in_2004 dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Companies_based_in_Redwood_City,_California
rdf:type	owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation
rdfs:comment	OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by and delisted from the Nasdaq. (en)
rdfs:label	OncoMed (en)
owl:sameAs	freebase:OncoMed yago-res:OncoMed wikidata:OncoMed https://global.dbpedia.org/id/niWs dbr:OncoMed
skos:closeMatch	http://www.grid.ac/institutes/grid.467496.e
prov:wasDerivedFrom	wikipedia-en:OncoMed?oldid=1112516297&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:OncoMed
foaf:name	OncoMed Pharmaceuticals, Inc. (en)
is dbo:wikiPageRedirects of	dbr:Paul_Hastings_(pharmaceutical_executive) dbr:OncoMed_Pharmaceuticals dbr:OncoMed_Pharmaceuticals,_Inc.
is dbo:wikiPageWikiLink of	dbr:Paul_Hastings_(pharmaceutical_executive) dbr:Vantictumab dbr:Compugen_(Israeli_company) dbr:Celgene dbr:NeXT dbr:OncoMed_Pharmaceuticals dbr:Seaport_Centre dbr:OncoMed_Pharmaceuticals,_Inc.
is foaf:primaryTopic of	wikipedia-en:OncoMed